Clostridium difficile: Novel insights on an incessantly challenging disease

Current Opinion in Infectious Diseases

Volumn 25, Issue 4, 2012, Pages 405-411

  Tschudin Sutter, Sarah ^a   Widmer, Andreas F ^b   Perl, Trish M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Clostridium difficile; diagnostic assays; epidemiology; polymerase chain reaction ribotype 027

Indexed keywords

BACITRACIN; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID VACCINE; FIDAXOMICIN; FUSIDIC ACID; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; FOOD CHAIN; HEALTHCARE ASSOCIATED INFECTION; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION RISK; INTESTINE FLORA; NONHUMAN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INCIDENCE; POLYMERASE CHAIN REACTION; RISK FACTORS; WORLD HEALTH;

EID: 84863725644     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835533a2     Document Type: Review

References (86)

1. Oake N, Taljaard M, van Walraven C, et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med 2010; 170:1804-1810.
2. McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18:282-289.
3. Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibioticassociated pseudomembranous colitis. Gastroenterology 1978; 75:778-782. (Pubitemid 9040959)
4. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-415.
5. Elixhauser A, Jhung M. Clostridium difficile-associated disease in US hospitals, 1993-2005. Rockville, MD: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Statistical Brief #50; 2006.
6. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US healthcare facility inpatients, 2008. Am J Infect Control 2009; 37:263-270.
7. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic inQuebec. Clin Infect Dis 2005; 41:1254-1260. (Pubitemid 41532667)
8. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449. (Pubitemid 41770165)
9. O'Donoghue C, Kyne L. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011; 27:38-47.
10. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73.
11. Gerding DN. Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 2010; 31 (Suppl 1):S32-S34.
12. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47:1162-1170.
13. Riley TV, Thean S, Hool G, Golledge CL. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 2009; 190:706-708.
14. Tae CH, Jung SA, Song HJ, et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 2009; 24:520-524.
15. Kim H, Lee Y, Moon HW, et al. Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lab Med 2011; 31:191-196.
16. Lim PL, Ling ML, Lee HY, et al. Isolation of the first three cases of Clostridium difficile polymerase chain reaction ribotype 027 in Singapore. Singapore Med J 2011; 52:361-364.
17. Cheng VC, Yam WC, Chan JF, et al. Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents 2009; 34:492-493.
18. Kato H, Ito Y, van den Berg RJ, et al. First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007; 12:E0701113.
19. Quesada-Gomez C, Rodriguez C, Gamboa-Coronado Mdel M, et al. Emergence of Clostridium difficile NAP1 in Latin America. J Clin Microbiol 2010; 48:669-670.
20. Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010; 10:395-404.
21. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk: four states 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201-1205.
22. Garey KW, Jiang ZD, Yadav Y, et al. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol 2008; 199:332-337.
23. Rouphael NG, O'Donnell JA, Bhatnagar J, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol 2008; 198:635; e1-e6.
24. Venugopal AA, Gerding DN, Johnson S. Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clostridium difficile isolates. Am J Infect Control 2011; 39:206-211.
25. Unger JA, Whimbey E, Gravett MG, Eschenbach DA. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol 2011; 2011:267249.
26. Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007; 28:1233-1235. (Pubitemid 47596560)
27. Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604-609.
28. Kasper AM, Nyazee HA, Yokoe DS, et al. A multicenter study of Clostridium difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol 2012; 33:470-476.
29. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15:1053-1066.
30. Deshpande A, Pasupuleti V, Rolston DD, et al. Diagnostic accuracy of realtime polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a metaanalysis. Clin Infect Dis 2011; 53:e81-e90.
31. Babady NE, Stiles J, Ruggiero P, et al. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol 2010; 48:4519-4524.
32. Bartlett JG. Detection of Clostridium difficile infection. Infect Control Hosp Epidemiol 2010; 31 (Suppl 1):S35-S37.
33. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985; 47:349-352. (Pubitemid 15169828)
34. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-1179.
35. Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-713.
36. Steele J, Chen K, Sun X, et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 2012; 205:384-391.
37. Bacci S, Molbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011; 17:976-982.
38. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-1703.
39. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784-790.
40. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 142:490-496.
41. Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011; 53:1173-1178.
42. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170:772-778.
43. DuPont HL. The search for effective treatment of Clostridium difficile infection. N Engl J Med 2011; 364:473-475.
44. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-1775. (Pubitemid 34761404)
45. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-764. (Pubitemid 43363928)
46. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004; 48:2280-2282. (Pubitemid 38691631)
47. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008; 52:4163-4165.
48. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 48:4898-4902. (Pubitemid 39577704)
49. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008; 52:1391-1395. (Pubitemid 351522003)
50. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.
51. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440-447.
52. Drekonja DM, Butler M, Macdonald R, et al. Comparative effectiveness of clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155:839-847.
53. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 20119:CD004610.
54. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633-637.
55. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41:366-370. (Pubitemid 27428197)
56. Warny M, Denie C, Delmee M, Lefebvre C. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 1995; 50:36-39.
57. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control 2007; 35:131-137. (Pubitemid 46283599)
58. Saito T, Kimura S, Tateda K, et al. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J Antimicrob Chemother 2011; 66:1096-1099.
59. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
60. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44:854-859.
61. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
62. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent clostridium difficile infection. Gastroenterology 2012; 142:490-496.
63. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13:97-101. (Pubitemid 15030800)
64. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-389. (Pubitemid 24033753)
65. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608-1610. (Pubitemid 36254357)
66. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988-995. (Pubitemid 32109565)
67. Seregin SS, Aldhamen YA, Rastall DP, et al. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 2012; 30:1492-1501.
68. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-770. (Pubitemid 40585378)
69. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010; 51:1306-1313.
70. Gould LH, Limbago B. Clostridium difficile in food and domestic animals: a new foodborne pathogen? Clin Infect Dis 2010; 51:577-582.
71. Songer JG, Trinh HT, Killgore GE, et al. Clostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis 2009; 15:819-821.
72. Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis 2007; 13:485-487. (Pubitemid 46348139)
73. Rodriguez-Palacios A, Reid-Smith RJ, Staempfli HR, et al. Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg Infect Dis 2009; 15:802-805.
74. Bakri MM, Brown DJ, Butcher JP, Sutherland AD. Clostridium difficile in readyto-eat salads, Scotland. Emerg Infect Dis 2009; 15:817-818.
75. Von Abercron SM, Karlsson F, Wigh GT, et al. Low occurrence of Clostridium difficile in retail ground meat in Sweden. J Food Prot 2009; 72:1732-1734.
76. Hoffer E, Haechler H, Frei R, Stephan R. Low occurrence of Clostridium difficile in fecal samples of healthy calves and pigs at slaughter and in minced meat in Switzerland. J Food Prot 2010; 73:973-975.
77. Koene MG, Mevius D, Wagenaar JA, et al. Clostridium difficile in Dutch animals: their presence, characteristics and similarities with human isolates. Clin Microbiol Infect 2011. [Epub ahead of print]
78. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
79. Dubberke ER. Prevention of healthcare-associated Clostridium difficile infection: what works? Infect Control Hosp Epidemiol 2010; 31 (Suppl 1):S38-S41.
80. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66:2168-2174.
81. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53:42-48.
82. Best EL, Fawley WN, Parnell P, Wilcox MH. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 2010; 50:1450-1457.
83. Best EL, Sandoe JA, Wilcox MH. Potential for aerosolization of Clostridium difficile after flushing toilets: the role of toilet lids in reducing environmental contamination risk. J Hosp Infect 2012; 80:1-5.
84. Galvin S, Boyle M, Russell RJ, et al. Evaluation of vaporized hydrogen peroxide, Citrox and pH neutral Ecasol for decontamination of an enclosed area: a pilot study. J Hosp Infect 2012; 80:67-70.
85. Nerandzic MM, Cadnum JL, Pultz MJ, Donskey CJ. Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms. BMC Infect Dis 2010; 10:197.
86. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979; 121:1193-1254.